au100 10 proa kit recombinant human cd44 fc chimera r d systems  (R&D Systems)

Journal: The Journal of Biological Chemistry

Article Title: Modulation of galectin-9 mediated responses in monocytes and T-cells by pregnancy-specific glycoprotein 1

doi: 10.1016/j.jbc.2024.107638

Figure Lengend Snippet: Kinetics constants and apparent affinity of the interaction of CD44, Tim-3 and native PSG1, and recombinant Psg23 with full-length (FL) GAL-9

Article Snippet: Recombinant human CD44 (catalog# 3660-CD) and TGF-β were purchased from R&D systems (catalog# 246-LP/CF).

Techniques: Recombinant

Journal: The Journal of Biological Chemistry

Article Title: Modulation of galectin-9 mediated responses in monocytes and T-cells by pregnancy-specific glycoprotein 1

doi: 10.1016/j.jbc.2024.107638

Figure Lengend Snippet: PSG1 can inhibit the binding of GAL-9 to Tim-3 and CD44. A , sensorgrams of the interaction of GAL-9 with CD44. Serial dilutions of GAL-9 ranging from 2 to 25 nM were injected during 3 min over a CM5 biosensor chip with immobilized native CD44. SPR sensorgrams for each protein concentration are shown as gray lines while the fitted data are shown as black lines . B , sensorgrams of the interaction of GAL-9 with Tim-3 represented as in A. Serial dilutions of GAL-9 ranging from 10 to 50 nM were injected during 3 min over a CM5 biosensor chip with immobilized native Tim-3. C , sensorgrams of the interaction of 25 nM GAL-9 preincubated with recombinant PSG1 injected over a biosurface of immobilized CD44. GAL-9 and PSG1 were preincubated at the indicated molar ratio and injected during 3 min over a CM5 biosensor chip with immobilized recombinant CD44. D , sensorgrams of the interaction of 25 nM GAL-9 preincubated with recombinant PSG1 at the indicated molar ratio injected over a biosurface with immobilized Tim-3. E , SPR sensorgram showing the interaction of 25 nM GAL-9 or preincubated with 25 nM PSG1 produced in CHOK1 (PSG1) or GnTI-deficient cells (PSG1GnTI - ) before injection over a biosurface of immobilized TIM3. GAL-9, galectin 9; PSG, pregnancy-specific glycoprotein; SPR, surface plasmon resonance; Tim-3, T-cell immunoglobulin mucin-3.

Article Snippet: Recombinant human CD44 (catalog# 3660-CD) and TGF-β were purchased from R&D systems (catalog# 246-LP/CF).

Techniques: Binding Assay, Injection, Protein Concentration, Recombinant, Produced, SPR Assay

Journal: Bioactive materials

Article Title: Advanced bioactive glue tethering Lubricin/PRG4 to promote integrated healing of avascular meniscus tears.

doi: 10.1016/j.bioactmat.2023.04.026

Figure Lengend Snippet: Fig. 7. CD44, a transmembrane glycoprotein, has a reported binding affinity to HA, lubricin, and fibrin(ogen) (A). CD44 readily bound on the articular surface of meniscus where lubricin was present, but not on NaCl-treated surface with depleted lubricin (B).

Article Snippet: CD44 (3660-CD-050, R&D Systems), lubricin (aa1151-1241, LSBio, Seattle WA), hyaluronic acid methacrylate (914800, SigmaAldrich), and/or type II collagen (COL-II) (C9301, Sigma-Aldrich) were co-labeled with multiple fluorescent secondary antibodies to track recruitment and differentiation of endogenous syMSCs.

Techniques: Binding Assay

Journal: Bioactive materials

Article Title: Advanced bioactive glue tethering Lubricin/PRG4 to promote integrated healing of avascular meniscus tears.

doi: 10.1016/j.bioactmat.2023.04.026

Figure Lengend Snippet: Fig. 8. Heparin conjugated FibGen incorporated with CD44 (Hep-FibGen-CD44) (A) showed significantly higher lap shear modulus and strength compared to FibGen on lubricin-coated meniscal tissues, with no significant difference from FibGen-CD44 (B) (*:p < 0.001; n = 10 per group). In contrast, Hep-FibGen-CD44 showed significantly higher lap shear and modulus as compared to Hep-FibGen on HA/lubricin-coated meniscal tissues (C) (*:p < 0.001 compared to FibGen, #:p < 0.001 compared to Hep-FibGen; n = 10 per group). Histologically, delivery of CTGF and TGFβ3-μS via Hep-FibGen-CD44 and Hep-FibGen improved the healing of avascular meniscus tears as compared to FibGen (D) (dash-line: healing zone). Quantitative histomorphometry measurements show significant improvement of tissue integration with FibGen-CD44 and Hep-FibGen-CD44 (E) (*:p < 0.001 compared to FibGen, #:p < 0.001 compared to FibGen-CD44; n = 5 per group). By 6 weeks, the tensile modulus and strength (F) of healed meniscus were significantly higher with CD44 incorporation and heparin conjugation than FibGen (*:p < 0.001 compared to FibGen, #:p < 0.001 compared to FibGen-CD44; n = 6–7 per group).

Article Snippet: CD44 (3660-CD-050, R&D Systems), lubricin (aa1151-1241, LSBio, Seattle WA), hyaluronic acid methacrylate (914800, SigmaAldrich), and/or type II collagen (COL-II) (C9301, Sigma-Aldrich) were co-labeled with multiple fluorescent secondary antibodies to track recruitment and differentiation of endogenous syMSCs.

Techniques: Shear, Conjugation Assay

Journal: Bioactive materials

Article Title: Advanced bioactive glue tethering Lubricin/PRG4 to promote integrated healing of avascular meniscus tears.

doi: 10.1016/j.bioactmat.2023.04.026

Figure Lengend Snippet: Fig. 9. Speculated mechanism for synergistic effect of heparin conjugation and CD44 incorporation on yielding strong binding to HA- and lubricin-coated meniscus surface. Although specific binding domain, mechanism, and affinity between each other components have been incompletely described, the cross- binding affinity between HA, lubricin, fibrinogen, heparin, and CD44 may have potential to achieve a strong initial binding of our bioactive glue on HA/ lubricin-deposited meniscus surface.

Article Snippet: CD44 (3660-CD-050, R&D Systems), lubricin (aa1151-1241, LSBio, Seattle WA), hyaluronic acid methacrylate (914800, SigmaAldrich), and/or type II collagen (COL-II) (C9301, Sigma-Aldrich) were co-labeled with multiple fluorescent secondary antibodies to track recruitment and differentiation of endogenous syMSCs.

Techniques: Conjugation Assay, Binding Assay